Scarica l'app Stockscreener
8.81
0.90%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$8.89
Aprire:
$8.94
Volume 24 ore:
1.63M
Relative Volume:
0.70
Capitalizzazione di mercato:
$2.71B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-25.91
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-2.33%
1M Prestazione:
-8.61%
6M Prestazione:
-22.04%
1 anno Prestazione:
-25.40%
Intervallo 1D:
$8.725
$8.94
Intervallo di 1 settimana:
$8.545
$9.035
Portata 52W:
$8.545
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.81 | 2.71B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Inceptionr LLC Cuts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Treatment Market Size in the 7MM is expected - openPR
Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential - Insider Monkey
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year LowHere's What Happened - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Essex Investment Management Co. LLC - MarketBeat
Amicus Therapeutics at Leerink Conference: Path to Profitability By Investing.com - Investing.com Canada
Amicus Therapeutics stock hits 52-week low at $8.78 By Investing.com - Investing.com Canada
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Sees Significant Drop in Short Interest - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Oppenheimer Asset Management Inc. Trims Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - Defense World
Amicus Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Amicus Therapeutics Posts Robust 2024 Financial Growth - TipRanks
Y Intercept Hong Kong Ltd Purchases 85,951 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - GlobeNewswire
HealthInvest Partners AB Has $3.08 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
State of New Jersey Common Pension Fund D Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Transcend Capital Advisors LLC Buys 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wells Fargo & Company Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Amicus Therapeutics’ (FOLD) “Hold” Rating Reiterated at Needham & Company LLC - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Wells Fargo & Company Issues Pessimistic Forecast for Amicus Therapeutics (NASDAQ:FOLD) Stock Price - Defense World
Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock By Investing.com - Investing.com Australia
Amicus Therapeutics files prospectus for stock sales - Investing.com India
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Peregrine Capital Management LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Quotes, Forecast and News Summary - Benzinga
Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):